Document is current
Any future updates will be listed below
-
Authors
Ruan, Dan-Yun
Wei, Xiao-Li
Liu, Fu-Rong
Hu, Xi-Chun
Zhang, Jian
Ji, Dong-Mei
Huang, Ding-Zhi
Zhao, Yan-Qiu
Pan, Hong-Min
Liao, Wang-Jun
Yang, Kun-Yu
Xu, Nong
Lu, Xiao-Xiao
Chen, Yu-Ling
Zhang, Wen
Zhou, Hui
Zhao, Hong-Yun
Xu, Rui-Hua
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 25 November 2024
First Online: 29 November 2024
Declarations
:
: The study protocol and all amendments were approved by the Institutional Review Boards of all participating institutions. All participants provided written informed consent. The study was performed in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.
: Not applicable.
: Xiao-Xiao Lu, Yu-Ling Chen, Wen Zhang, Hui Zhou are employees of Innovent Biologics (Suzhou) Co. Ltd. Rui-Hua Xu reports speaker fees from Bristol Myers Squibb, Roche, MerckSerono, Hutchison, Hengrui, Junshi, Qilu, CPPC, Henlius, and participates on advisory board for Astellas, MSD, AstraZeneca, Junshi, Hengrui, BeiGene. Innovent, CPPC, and Keymed.
